Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î]½É¾ß½Ã°£ ¾à±¹ ÀÌ¿ë '¸¸Á·ÇÑ´Ù' 93.5%
³»   ¿ë
Âü¿© ¿¬±¸¿ø ÀÓÀ翵 ½ÇÀå/±èÁøÀ̠åÀÓ¿¬±¸¿ø/Á¤µ¿¿í ºÎ¼±ÀÓ¿¬±¸¿ø
ÆíÁý ÀÌÁÖÇÏ ÁÖÀÓ¿¬±¸¿ø


<Áö³­È£¿¡ À̾>
2. Á¦ÁÖµµ¹Î ´ë»ó ½É¾ß¾à±¹ ¸¸Á·µµ Á¶»ç


(1) Á¦ÁÖµµ¹Î ´ë»ó Á¶»ç 
Á¦ÁÖµµ °ø°ø½É¾ß¾à±¹¿¡ ´ëÇÑ Á¦ÁÖµµ¹ÎÀÇ ÀÎÁöµµ ¹× ¸¸Á·µµ Á¶»ç´Â 2020³â 10¿ù 26ÀÏ¡­2020³â 11¿ù 4ÀϱîÁö Àü¹® Á¶»ç¿ä¿ø¿¡ ÀÇÇØ ÀüÈ­Á¶»ç·Î ½ÃÇàµÆ´Ù.

Á¶»ç¹æ¹ýÀº ¹«ÀÛÀ§ ÀüÈ­°É±â(Random Digit Dialing, RDD)¿´À¸¸ç, Á¶»ç ´ë»óÀڴ Á¦ÁÖµµ¹Î ¸¸ 20´ë¡­60´ë ³²³à ¼ºÀÎÀ¸·Î¼­ Á¶»ç °á°úÀÇ ´ëÇ¥¼º È®º¸¸¦ À§ÇØ Áö¿ªº°¡¤¼ºº°¡¤¿¬·Éº°·Î 300¸íÀ» Ç¥º»ÃßÃâÇØ ±¸¼ºÇß´Ù.

°ø°ø½É¾ß¾à±¹À» ¾Ë°í ÀÖ´Ù°í ´äÇÑ ÀÀ´äÀÚ(22.3%)ÀÇ ºñÀ²ÀÌ ¸ð¸¥´Ù°í ´äÇÑ ÀÀ´äÀÚÀÇ ºñÀ²(77.7%) º¸´Ù ÇöÀúÈ÷ ³·À½À» ¾Ë ¼ö ÀÖ¾ú´Ù<±×¸²3 ÂüÁ¶>.

°ø°ø½É¾ß¾à±¹À» ÀÎÁöÇϰí Àִ ÀÀ´äÀڵ鿡°Ô ÀÎÁö°æ·Î¸¦ Á¶»çÇß´Ù. Á¶»ç °á°ú °¡Á· µî ÁöÀÎÀÌ ¾Ë·ÁÁØ °æ¿ì°¡ 28.4%·Î °¡Àå ¸¹¾ÒÀ¸¸ç, Àü±¤ÆÇÀ̳ª ¾à±¹ °£ÆÇÀ» º¸°í ¾Ë°Ô µÈ °æ¿ì°¡ 25.4%·Î ±× µÚ¸¦ À̾ú´Ù. ÅÚ·¹ºñÀü, ¶óµð¿À, ½Å¹® µîÀÇ ¾ð·ÐÀ» ÅëÇØ¼­ ¾Ë°Ô µÈ °æ¿ì°¡ 22.4%¿´À¸¸ç, ÀÎÅͳݠÀ¥ »çÀÌÆ®³ª ¼Ò¼È³×Æ®¿öÅ© ¼­ºñ½º¸¦ ÅëÇØ ¾Ë°Ô µÈ °æ¿ì´Â 17.9%·Î ³ªÅ¸³µ´Ù. ±âŸ ÀǰßÀ¸·Î´Â 119¸¦ ÅëÇØ¼­, º´¿ø¿¡¼­ Á¤º¸¸¦ ¾òÀ½ µîÀÌ ÀÖ¾ú´Ù<±×¸²4 ÂüÁ¶>.


½É¾ß½Ã°£´ë ¾à±¹À» ÀÌ¿ëÇϱâ À§Çؼ­ Áý¿¡¼­ Ãâ¹ß ÈÄ ¾à±¹¿¡ µµÂøÇÒ ¶§ ±îÁö °É¸° ½Ã°£À» ¹¯´Â Áú¹®¿¡ 48.7%ÀÇ ÀÀ´äÀÚ°¡ 10ºÐ ÀÌ»ó¡­30ºÐ ¹Ì¸¸ÀÇ ½Ã°£ÀÌ ¼Ò¿äµÈ´Ù°í ´äÇß´Ù. 10ºÐ ¹Ì¸¸ÀÇ ½Ã°£ÀÌ ¼Ò¿äµÈ´Ù°í ´äÇÑ ºñÀ²Àº 40.8%·Î ³ªÅ¸³µÀ¸¸ç, 30ºÐ ÀÌ»ó ¼Ò¿äµÇ´Â °æ¿ìµµ 10.5%·Î ³ªÅ¸³µ´Ù<±×¸²5 ÂüÁ¶>.


½É¾ß¾à±¹À» ¹æ¹®ÇϰԠµÈ °¡Àå ÁֵȠÀÌÀ¯¸¦ ¹¯´Â Áú¹®¿¡ 90.8%ÀÇ ÀÀ´äÀÚ°¡ 'ÇÊ¿äÇÑ ¾àÀ» ±¸ÀÔÇØ ÀÀ±Þ»óȲÀ» ÇذáÇϱâ À§Çؼ­'¶ó°í ´äÇß´Ù. 6.6%ÀÇ ÀÀ´äÀڴ '°³ÀΠ¿©°Ç»ó ³· ½Ã°£´ë ¾à±¹¹æ¹®ÀÌ ¾î·Æ±â ¶§¹®¿¡ ½É¾ß½Ã°£´ë ¾à±¹À» ÀÌ¿ëÇß´Ù'°í ´äÇß´Ù<±×¸²6 ÂüÁ¶>.


½É¾ß½Ã°£´ë ¾à±¹À» ÀÌ¿ëÇÑ Á¦ÁÖµµ¹Î¿¡°Ô ¸¸Á·µµ Á¶»ç¸¦ Çß´Ù. ¾à±¹À» ÀÌ¿ëÇÑ ÀÌÀ¯¿Í ¸ñÀû¿¡ ºñÃç À̿렰á°ú¿¡ ´ëÇØ ¸¸Á·ÇÏ´ÂÁö ¹®ÀÇÇÑ °á°ú ¸Å¿ì ¸¸Á·(51.9%), ¾à°£ ¸¸Á·(41.6%)·Î ³ªÅ¸³µ´Ù. ¾à°£ ºÒ¸¸Á·À̶ó°í ´äÇÑ ÀÀ´äÀڴ 3.9%¿´À¸¸ç ¸Å¿ì ºÒ¸¸Á·À¸·Î ´äÇÑ ÀǰßÀº 2.6%·Î Á¶»çµÆ´Ù. 

½É¾ß½Ã°£´ë ¾à±¹ À̿뿡 ´ëÇØ¼­ ¸¸Á·°ú ºÒ¸¸Á· µÎ ±ºÀ¸·Î ³ª´­ °æ¿ì, ¸¸Á·ÇѴٴ ÀÀ´äÀÌ 93.5%À̸砺Ҹ¸Á·ÇѴٴ ºñÀ²Àº 6.5%ÀΠ°ÍÀ¸·Î ³ªÅ¸³µ´Ù<±×¸²7 ÂüÁ¶>.


½É¾ß½Ã°£´ë ¾à±¹ÀÇ ÀÌ¿ëÀÚµéÀÇ ¸¸Á·µµ´Â ¸Å¿ì ³ôÀº ÆíÀ¸·Î ¸¸Á·ÇѴٴ ´äº¯ÀÌ 93.5%¿¡ ´ÞÇßÀ¸¸ç, 93%ÀÇ ÀÀ´äÀÚ°¡ ½É¾ß¾à±¹ÀÌ ÇÊ¿äÇÏ´Ù°í ´äÇß´Ù. Æ¯È÷, ½É¾ß¾à±¹À» ÀÌ¿ëÇØº» °æÇèÀÚ°¡ ½É¾ß¾à±¹ÀÌ ¸Å¿ì ÇÊ¿äÇÏ´Ù°í ´äÇØ(92%) ÀÎÁöµµ¿Í ºÒÆí»çÇ×ÀÌ ÇØ°áµÇ°í, ¾È³»¿Í È«º¸°¡ Àß ÀÌ·ïÁø´Ù¸é, ¸¹Àº µµ¹ÎµéÀÌ Çʿ䠽à½É¾ß½Ã°£´ë ¾à±¹À» ÀÌ¿ëÇÏ°í ¸¸Á·µµ°¡ Å¬ °ÍÀ¸·Î »ý°¢µÈ´Ù. <´ÙÀ½È£¿¡ °è¼Ó>

 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
129 [´ëÇѾà»çÀú³Î]°ø°ø½É¾ß¾à±¹, »ç¾÷ È®´ë À§ÇØ ¿î¿µ¡¤ÆíÀÇ °³¼± ÇÊ¿ä ÀÌÁÖÇÏ 2021-09-23 904
128 [´ëÇѾà»çÀú³Î]½É¾ß½Ã°£ ¾à±¹ ÀÌ¿ë '¸¸Á·ÇÑ´Ù' 93.5% ÀÌÁÖÇÏ 2021-09-23 783
127 [´ëÇѾà»çÀú³Î]¿µ±¹, OHH ¼­ºñ½º ÀϹݾࡤÀü¹®¾à ³ª´² Á¦°ø ÀÌÁÖÇÏ 2021-09-23 762
126 [´ëÇѾà»çÀú³Î]È£ÁÖ ¹ãÀ» ¹àÈ÷´Â 'Supercare' ¾à±¹ ÀÌÁÖÇÏ 2021-09-23 768
125 [ÀǾàǰÁ¤Ã¥¸®Æ÷Æ®]ÀÀ´äÀÚ 94.3% µµÀÔ Âù¼º¡¦Àü¹®Àû »ó´ã Àý½Ç ÀÌÁÖÇÏ 2021-09-23 252
124 [´ëÇѾà»çÀú³Î] ¾à ±¸ÀÔ ½Ã ¾à»ç¿Í »ó´ãÀÌ Áß¿ä 85% ÀÌÁö¿¬ 2021-08-10 522
123 [´ëÇѾà»çÀú³Î] ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° 'µµ¿òµÆ´Ù' 98% ÀÌÁö¿¬ 2021-08-02 462
122 [´ëÇѾà»çÀú³Î] ¾ÆÆí ÇÔÀ¯ 'Á¤ÅëÆí' ÅëÁõ ¸¸º´ÅëÄ¡¾àó·³ »ç¿ë ÀÌÁö¿¬ 2021-08-02 507
121 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠó¹æÀǾàǰ È¿°ú ½Å·Ú ´õ ³ô¾Æ ÀÌÁö¿¬ 2021-07-21 451
120 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠÀǾàǰ Àνİú »ç¿ë ÇöȲÀº? ÀÌÁö¿¬ 2021-07-14 392
119 [´ëÇѾà»çÀú³Î] "ºÎÀÛ¿ë °æÇè 98% Áõ»ó ½Å°í¾ÈÇØ" ºÒ°¨Áõ ½É°¢ ÀÌÁö¿¬ 2021-07-07 467
118 [´ëÇѾà»çÀú³Î] ¾ÈÀü»óºñÀǾàǰ ±¸ÀÔ ¿äÀÏ ÁÖ¸» '50.3%' Â÷Áö ÀÌÁö¿¬ 2021-06-29 456
117 [´ëÇѾà»çÀú³Î] ±¹¹Î 90% 1³â°£ ÆíÀÇÁ¡ »óºñ¾à ÃÖ´ë 5ȸ ±¸ÀÔ ÀÌÁö¿¬ 2021-06-22 489
116 [´ëÇѾà»çÀú³Î] ÆíÀÇÁ¡ ºøÀå Ç®¸®ÀÚ ½ñ¾ÆÁø °¨±â¾à¡¤ÁøÅëÁ¦ ÀÌÁö¿¬ 2021-06-16 435
115 [´ëÇѾà»çÀú³Î] Áö¿ª¾à±¹ '»ý¸íÁöÅ´ÀÌ' ¿ªÇÒ ¼öÇà °ü½É ³ôÇû´Ù ÀÌÁö¿¬ 2021-06-09 444

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»